The dynamic broad epigenetic (H3K4me3, H3K27ac) domain as a mark of essential genes
TH Beacon, GP Delcuve, C López, G Nardocci… - Clinical …, 2021 - Springer
Transcriptionally active chromatin is marked by tri-methylation of histone H3 at lysine 4
(H3K4me3) located after first exons and around transcription start sites. This epigenetic mark …
(H3K4me3) located after first exons and around transcription start sites. This epigenetic mark …
The H2A. Z-nucleosome code in mammals: emerging functions
H2A. Z is a histone variant that provides specific structural and docking-side properties to the
nucleosome, resulting in diverse and specialised molecular and cellular functions. In this …
nucleosome, resulting in diverse and specialised molecular and cellular functions. In this …
Insights into the genetic architecture of the human face
The human face is complex and multipartite, and characterization of its genetic architecture
remains challenging. Using a multivariate genome-wide association study meta-analysis of …
remains challenging. Using a multivariate genome-wide association study meta-analysis of …
[HTML][HTML] CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis
MA Augello, D Liu, LD Deonarine, BD Robinson… - Cancer Cell, 2019 - cell.com
Deletion of the gene encoding the chromatin remodeler CHD1 is among the most common
alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and …
alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and …
Sentinels of chromatin: chromodomain helicase DNA-binding proteins in development and disease
A Alendar, A Berns - Genes & Development, 2021 - genesdev.cshlp.org
Chromatin is highly dynamic, undergoing continuous global changes in its structure and
type of histone and DNA modifications governed by processes such as transcription, repair …
type of histone and DNA modifications governed by processes such as transcription, repair …
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
T Sugawara, SJ Baumgart… - … Journal of Cancer, 2019 - Wiley Online Library
Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure
compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer …
compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer …
Genome scans of facial features in East Africans and cross-population comparisons reveal novel associations
Facial morphology is highly variable, both within and among human populations, and a
sizable portion of this variation is attributable to genetics. Previous genome scans have …
sizable portion of this variation is attributable to genetics. Previous genome scans have …
Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
SJ Baumgart, E Nevedomskaya, R Lesche… - Molecular …, 2020 - Wiley Online Library
Prostate cancer (PCa) is one of the most frequent tumor types in the male Western
population. Early‐stage PCa and late‐stage PCa are dependent on androgen signaling …
population. Early‐stage PCa and late‐stage PCa are dependent on androgen signaling …
MATN1‐AS1 promotes glioma progression by functioning as ceRNA of miR‐200b/c/429 to regulate CHD1 expression
J Zhu, WT Gu, C Yu - Cell Proliferation, 2020 - pmc.ncbi.nlm.nih.gov
Objectives Long non‐coding RNA (lncRNA) MATN1‐AS1 is a newfound lncRNA that has
been rarely explored in cancers. Herein, we would like to investigate its role in glioma …
been rarely explored in cancers. Herein, we would like to investigate its role in glioma …
3D facial phenotyping by biometric sibling matching used in contemporary genomic methodologies
The analysis of contemporary genomic data typically operates on one-dimensional
phenotypic measurements (eg standing height). Here we report on a data-driven, family …
phenotypic measurements (eg standing height). Here we report on a data-driven, family …